Wikipedia

User:Mr. Ibrahem/Tiagabine

< User:Mr. Ibrahem
Mr. Ibrahem/Tiagabine
Clinical data
Pronunciation/taɪˈæɡəbiːn/
Trade namesGabitril
AHFS/Drugs.comMonograph
MedlinePlusa698014
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth (tablets)
Legal status
Legal status
Pharmacokinetic data
Bioavailability90–95%[1]
Protein binding96%[1]
MetabolismLiver (CYP450 system,[1] primarily CYP3A)[3]
Elimination half-life5–8 hours[2]
ExcretionFecal (63%) and kidney (25%)[3]
Identifiers
  • (−)-(3R)-1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid
Chemical and physical data
FormulaC20H25NO2S2
Molar mass375.55 g·mol−1
3D model (JSmol)
  • O=C(O)[C@H]1CN(CCC1)CC/C=C(/c2sccc2C)c3sccc3C
  • InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1 checkY
  • Key:PBJUNZJWGZTSKL-MRXNPFEDSA-N checkY
  (verify)

Tiagabine, sold under the brand name Gabitril, is a medication primarily used to treat epilepsy.[4] Specifically it is used for partial seizure that are not controllable by other measures.[4] Use for other disorders is discouraged.[4] It is taken by mouth, usually with food in divided doses over the day, starting at a small dose and increased gradually.[6]

Common side effects include tiredness, sleepiness, nausea, irritability, pain, and trouble sleeping.[4] In certain types of epilepsy, it may increase seizure frequency.[5] Other side effects may include suicide and Stevens-Johnson syndrome.[4] While safety in pregnancy is unclear, there are concerns it may harm the baby.[4] It is believed to work by affecting γ-aminobutyric acid (GABA).[4]

Tiagabine was approved for medical use in the United States in 1997.[4] In the United Kingdom 100 tablets of 10 mg costs the NHS about £104 as of 2021.[5] This amount in the United States costs about 300 USD.[7][8]

References edit

  1. ^ a b c Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 562–. ISBN 978-1-60913-345-0. Archived from the original on 29 August 2021. Retrieved 13 January 2021.
  2. ^ Brodie, Martin J. (1995). "Tiagabine Pharmacology in Profile". Epilepsia. 36 (s6): S7–S9. doi:10.1111/j.1528-1157.1995.tb06015.x. ISSN 0013-9580. PMID 8595791. S2CID 27336198.
  3. ^ a b "Gabitril (tiagabine hydrochloride) Tablets. U.S. Full Prescribing Information" (PDF). Cephalon, Inc. Archived (PDF) from the original on 2 April 2016. Retrieved 8 April 2016.
  4. ^ a b c d e f g h i j "TiaGABine Monograph for Professionals". Drugs.com. Archived from the original on 19 January 2021. Retrieved 3 October 2021.
  5. ^ a b c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 348. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  6. ^ Rogawski, Michael A. (2020). "24. Antiseizure drugs". In Katzung, Bertram G.; Trevor, Anthony J. (eds.). Basic and Clinical Pharmacology (15th ed.). New York: McGraw-Hill. p. 434. ISBN 978-1-260-45231-0. Archived from the original on 2021-10-10. Retrieved 2021-11-08.
  7. ^ "TiaGABine Monograph for Professionals". Drugs.com. Archived from the original on 19 January 2021. Retrieved 3 October 2021.
  8. ^ "Gabitril Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 5 May 2016. Retrieved 4 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Tiagabine&oldid=1210336153"